Etiasa (mesalazine) / Ipsen, Ethypharm - LARVOL DELTA

[Retracted] Effect of Etiasa on the expression of matrix metalloproteinase‑2 and tumor necrosis factor‑α in a rat model of ulcerative colitis. (PubMed, Mol Med Rep) - "The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 6: 996‑1000, 2012; DOI: 10.3892/mmr.2012.1021]."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis • MMP2 • TNFA

Ethypharm expands its Mesalazine (Etiasa) Portfolio in China (PRNewswire) - "Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical....Mesalazine is a medication used to treat Inflammatory Bowel Diseases (IBD) such as ulcerative colitis and Crohn's disease."

M&A • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis